Carcinoma of Unknown Original Identified As Renal Cell Carcinoma by 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scan: A Report of Two Cases

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2022 Nov 7

PMID 36337777

Authors

Yumiko Kono

Keita Utsunomiya

Chisato Ohe

Nae Takizawa

Noboru Tanigawa

Affiliations

Soon will be listed here.

Abstract

Imaging is useful in identifying the primary site of an unknown primary cancer, and F-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) is an excellent imaging modality for identifying the primary lesion. However, a potential limitation is that F-FDG is physiologically excreted from the kidneys, thus masking renal lesions. In this report, we describe two cases of cancer of unknown origin that were detected as originating from renal cancer on F-FDG PET/CT. Both cases showed abnormal nodular accumulation of F-FDG in the kidney, which can be distinguished from the physiological excretion of F-FDG in the urinary tract. It is clinically crucial to be able to confirm the possibility of renal cancer, and careful observation of the urinary tract with F-FDG PET/CT can be useful.

Citing Articles

Solitary vertebral metastasis of unknown primary renal cell carcinoma treated with surgical resection plus tyrosine kinase inhibitor: A case report.

Abian N, Momen O, Esfandiari F, Azarhoush R Int J Surg Case Rep. 2024; 114:109217.

PMID: 38171274 PMC: 10800757. DOI: 10.1016/j.ijscr.2023.109217.

Combined Immunotherapy and Tyrosine Kinase Inhibitor Treatment for Metastatic Renal Cell Carcinoma With Unknown Primary Origin: A Report of Two Cases and Literature Review.

Chen H, Yu L, Chang H, Huang W, Lin W, Chang C In Vivo. 2023; 37(4):1905-1913.

PMID: 37369518 PMC: 10347932. DOI: 10.21873/invivo.13285.

References

Kwee T, Kwee R . Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol. 2008; 19(3):731-44. PMC: 2816234. DOI: 10.1007/s00330-008-1194-4. View

Ozulker T, Ozulker F, Ozbek E, Ozpacaci T . A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses. Nucl Med Commun. 2011; 32(4):265-72. DOI: 10.1097/MNM.0b013e3283442e3b. View

Takahashi M, Kume H, Koyama K, Nakagawa T, Fujimura T, Morikawa T . Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET/CT. Clin Nucl Med. 2015; 40(12):936-40. PMC: 4890815. DOI: 10.1097/RLU.0000000000000875. View

Mian B, Bhadkamkar N, Slaton J, Pisters P, Daliani D, Swanson D . Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol. 2001; 167(1):65-70. View

Shuch B, Said J, La Rochelle J, Zhou Y, Li G, Klatte T . Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable?. J Urol. 2009; 182(5):2164-71. PMC: 3175230. DOI: 10.1016/j.juro.2009.07.049. View

Greco F, Hainsworth J . Renal Cell Carcinoma Presenting as Carcinoma of Unknown Primary Site: Recognition of a Treatable Patient Subset. Clin Genitourin Cancer. 2018; 16(4):e893-e898. DOI: 10.1016/j.clgc.2018.03.001. View

Bedke J, Albiges L, Capitanio U, Giles R, Hora M, Lam T . The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care. Eur Urol. 2021; 80(4):393-397. DOI: 10.1016/j.eururo.2021.04.042. View

Burglin S, Hess S, Hoilund-Carlsen P, Gerke O . 18F-FDG PET/CT for detection of the primary tumor in adults with extracervical metastases from cancer of unknown primary: A systematic review and meta-analysis. Medicine (Baltimore). 2017; 96(16):e6713. PMC: 5406105. DOI: 10.1097/MD.0000000000006713. View

Wang H, Ding H, Chen J, Chao C, Lu Y, Lin W . Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging. 2012; 12:464-74. PMC: 3483599. DOI: 10.1102/1470-7330.2012.0042. View

10.

OConnor S, Silverman S, Cochon L, Khorasani R . Renal cancer at unenhanced CT: imaging features, detection rates, and outcomes. Abdom Radiol (NY). 2017; 43(7):1756-1763. PMC: 6546086. DOI: 10.1007/s00261-017-1376-0. View

11.

Rossi S, Klatte T, Usher-Smith J, Stewart G . Epidemiology and screening for renal cancer. World J Urol. 2018; 36(9):1341-1353. PMC: 6105141. DOI: 10.1007/s00345-018-2286-7. View

12.

Cetin Avci N, Hatipoglu F, Alacacioglu A, Bayar E, Bural G . FDG PET/CT and Conventional Imaging Methods in Cancer of Unknown Primary: an Approach to Overscanning. Nucl Med Mol Imaging. 2018; 52(6):438-444. PMC: 6261859. DOI: 10.1007/s13139-018-0544-7. View

13.

Kang D, White Jr R, Zuger J, Sasser H, Teigland C . Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol. 2004; 171(5):1806-9. DOI: 10.1097/01.ju.0000120241.50061.e4. View

14.

Urban D, Rao A, Bressel M, Lawrence Y, Mileshkin L . Cancer of unknown primary: a population-based analysis of temporal change and socioeconomic disparities. Br J Cancer. 2013; 109(5):1318-24. PMC: 3778275. DOI: 10.1038/bjc.2013.386. View